Company Announcement | Berlin, 19th June 2024
ALS‘s Strategic Acquisition Drives Innovation and Science
The global leader in testing, ALS Limited acquired NUVISAN on April 1, 2024, integrating advanced drug discovery, preclinical and clinical development capabilities into its growing portfolio. With ALS’s commitment to high-quality and personalized solutions spanning from drug discovery to post-commercialization, this strategic acquisition presents specific opportunities for our customers.
Company Announcement | Berlin, 28th March 2024
NUVISAN is the first Gyrolab® Certified CRO in the EU
NUVISAN proudly announces its achievement as the first Gyrolab® Certified CRO in the EU! Experience unmatched efficiency and rapid immunoassay solutions as we revolutionize research with our state-of-the-art Gyrolab® platforms.
Company Announcement | Neu-Ulm, 26th March 2024
ALS Takes Ownership of NUVISAN
With the acquisition of the remaining 51% shares by ALS, we are excited to join the ALS group and contribute to strengthening its pharmaceutical footprint in Europe. The announcement marks a significant milestone for us, representing an opportunity to expand and grow. Through ALS, we gain access to a global network of knowledge and innovation that will drive our development.
Company Announcement | Berlin, 19th September 2023
Celebrating Three Years of Fruitful Collaboration: NUVISAN ICB and Bayer Pharmaceuticals
Completing three years of collaboration, we value strategic partnerships for scientific advancement, with the goal of pushing scientific boundaries and impacting patients’ lives. Our collaboration will continue to progress.
Company Announcement | Berlin, 30th March 2023
NUVISAN Announces the First Winner of the 1st NUVISAN Drug Discovery Innovation Challenge: ARGO Therapeutics
To support an ecosystem of innovation for the benefit of human health and well-being, NUVISAN brings innovators and investors together and creates discussion and potential collaboration for drug discovery projects. We congratulate ARGO Therapeutics on being the first winner of the 1st NUVISAN Drug Discovery Innovation Challenge.
Company Announcement | Neu-Ulm, 7th March 2023
NUVISAN Awarded GMP Certificate for Carbon-14 APIs
From small-scale feasibility studies to large-scale GMP-compliant production, our team is specialized in radiolabeling APIs with different isotopes including stable isotope labeled NCEs (D, 13C, 15N) and radioactive labeled NCEs or peptides (3H, 14C), to support preclinical and clinical studies.
Company Announcement | Neu-Ulm, 12th October 2022
NUVISAN is Now a Biocrates Certified Laboratory For MxP® Quant 500 Kit
For targeted metabolomics assays, NUVISAN can now provide reproducible analysis for up to 630 metabolites and lipids per biological sample (usually 10 µl is sufficient) including both human and animal plasma, serum, tissue, feces, breast milk, cells and more.
Press Release | Berlin, 20th September 2022
NUVISAN receives US$ 9.6m grant for a multi-target drug discovery program on novel non-hormonal contraceptive medicines
NUVISAN ICB GmbH, a fully integrated contract research service provider for drug discovery and development (“NUVISAN ICB”), announced today that the company has received a grant from the Bill & Melinda Gates Foundation (Seattle, WA, USA, “the foundation”) for an integrated program on discovery and early development of novel non-hormonal contraceptive medicines.
→ Read Press Release (EN)
→ Read Press Release (DE)
→ Read Press Release (FR)
Partner Press Release | New York, 9th February 2022
Hoth Therapeutics Announces the selection of NUVISAN for Manufacturing HT-001 Drug Batches for CLEER-001 Clinical Study for Cancer Patients
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced it has signed an agreement with NUVISAN, a European CRO/CDMO with topical manufacturing capabilities in Sophia-Antipolis, France, to manufacture clinical batches of HT-001 topical drug product for its upcoming CLEER-001 clinical trial for cancer patients. HT-001 is a novel topical therapy in development for treatment of cutaneous toxicities associated with Epidermal Growth Factor Receptor (EGFR) inhibitor cancer therapy.
Press Release | Berlin & Brisbane, 28th July 2021
NUVISAN And ALS Limited Sign Strategic Partnership To Open New Markets
The NUVISAN group, a Contract Research Organization (CRO) and Contract Manufacturing Organization (CDMO), and ALS Limited, a global company in the testing, inspection and certification business, today announced the signing of a long term strategic partnership to open new markets. ALS Limited invests into a 49% stake of the NUVISAN group to expand its life sciences portfolio. The global testing specialist with its headquarters in Brisbane/ Australia supports NUVISAN's expansion strategy with its worldwide network.
Press Release | Berlin, 19th April 2021
ERS Genomics and NUVISAN ICB Sign CRISPR/Cas9 Licence Agreement
ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and NUVISAN Innovation Campus Berlin (ICB) GmbH, a fully integrated contract research service provider for drug discovery and early development programs, today announced a non-exclusive license agreement granting NUVISAN ICB access to ERS Genomics’ CRISPR/Cas9 patent portfolio.
Press Release | Berlin & Neu-Ulm, 18th August 2020 (EN)
INNOVATION CAMPUS BERLIN Is Partner To The EU Supported Programm Care (Corona Accelerated R&D Europe)
INNOVATION CAMPUS BERLIN is a proud Partner of Europe’s Largest Initiative to Accelerate Therapy Development for COVID-19 and Future Coronavirus Threats which is launched today in cooperation with the European Union, the European Federation of Pharmaceutical Industries, Associations (EFPIA) companies and IMI-Associated Partners.
Press Release | Berlin | Neu-Ulm, 1st July 2020
NUVISAN starts the „INNOVATION CAMPUS BERLIN“ (ICB) with over 400 workplaces
On the 1st of July, the "INNOVATION CAMPUS BERLIN" (ICB), a subsidiary of NUVISAN GmbH/ Neu-Ulm officially opened. NUVISAN has taken over a large part of the Berlin-based pharmaceutical research unit, focused on the field of small molecule active ingredients, from Bayer AG and agreed on a strategic partnership.
Press Release | Berlin & Neu-Ulm, 11th February 2020
BAYER And NUVISAN Create New Research Unit In Berlin
Das Pharma-Service Unternehmen NUVISAN hat mit Bayer die Übernahme eines großen Teils der in Berlin ansässigen Pharmaforschung auf dem Gebiet kleinmolekularer Wirkstoffe vereinbart und komplettiert damit sein Leistungsspektrum auf dem Gebiet der präklinischen Forschung.